Veracyte initiated with a Buy at UBS

UBS initiated coverage of Veracyte with a Buy rating and $43 price target The firm sees durable growth in its core products as well as long-term growth potential form minimal residual disease, or MRD, testing, the analyst tells investors. Continued market penetration and share gain should drive the next phase of growth, the analyst added.